David A. Siegel 89bio, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in 89bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 16,000 shares of ETNB stock, worth $236,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,000

Previous 24,800 35.48%

Holding current value

$236,320

Previous $180,000 12.78%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$4.83 - $10.57 $42,504 - $93,016	-8,800 Reduced 35.48%	16,000 $157,000
Q1 2025 May 15, 2025	SELL	$6.18 - $11.66 $539,514 - $1.02 Million	-87,300 Reduced 77.88%	24,800 $180,000
Q4 2024 Feb 14, 2025	SELL	$7.03 - $10.05 $359,233 - $513,555	-51,100 Reduced 31.31%	112,100 $859,000
Q3 2024 Nov 14, 2024	SELL	$7.36 - $9.66 $394,496 - $517,776	-53,600 Reduced 24.72%	163,200 $1.21 Million
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $535,823 - $798,970	73,300 Added 51.08%	216,800 $1.74 Million
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $193,494 - $327,726	-23,800 Reduced 14.23%	143,500 $1.67 Million
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $1.63 Million - $3.93 Million	-245,400 Reduced 59.46%	167,300 $1.87 Million
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $5.87 Million - $7.56 Million	-389,700 Reduced 48.57%	412,700 $6.37 Million
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $1.4 Million - $2.17 Million	-98,700 Reduced 10.95%	802,400 $15.2 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $856,216 - $1.38 Million	81,700 Added 9.97%	901,100 $13.7 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $1.45 Million - $3.34 Million	262,500 Added 47.14%	819,400 $10.4 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $1 Million - $2.32 Million	331,500 Added 147.07%	556,900 $3.22 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $108,679 - $209,039	52,000 Added 29.99%	225,400 $726,000
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $361,215 - $1.57 Million	104,700 Added 152.4%	173,400 $654,000
Q4 2021 Feb 14, 2022	SELL	$11.15 - $19.66 $259,795 - $458,078	-23,300 Reduced 25.33%	68,700 $898,000
Q3 2021 Nov 15, 2021	SELL	$14.91 - $21.31 $295,218 - $421,938	-19,800 Reduced 17.71%	92,000 $1.8 Million
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $337,948 - $543,200	-19,400 Reduced 14.79%	111,800 $2.09 Million
Q1 2021 May 17, 2021	BUY	$20.22 - $26.73 $54,594 - $72,171	2,700 Added 2.1%	131,200 $3.11 Million
Q4 2020 Feb 16, 2021	BUY	$23.16 - $28.08 $2.61 Million - $3.17 Million	112,800 Added 718.47%	128,500 $3.13 Million
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $382,138 - $609,474	15,700 New	15,700 $403,000

Others Institutions Holding ETNB

# of Institutions

215

Shares Held

161M

Call Options Held

299K

Put Options Held

1.61M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $687M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account